Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389256 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL29766823 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AMEN1 | |
| Hydrochloric Acid SCHEMBL9358749 | 0.99 | DRD2 (0.97) | DRD2DRD3DRD4HTR1AMEN1 | |
| Hydrochloric Acid SCHEMBL9309640 | 0.99 | DRD2 (0.97) | DRD2DRD3DRD4HTR1AMEN1 | |
| Hydrochloric Acid SCHEMBL9306802 | 0.99 | DRD2 (0.97) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL11267208 | 0.94 | DRD2 (0.88) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL11267207 | 0.94 | DRD2 (0.88) | DRD2DRD3DRD4HTR1AMEN1 | |
| Hydrochloric Acid SCHEMBL9307503 | 0.93 | DRD2 (0.86) | DRD2DRD3DRD4HTR1AMEN1 | |
| Hydrochloric Acid SCHEMBL9307498 | 0.93 | DRD2 (0.86) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL9559065 | 0.92 | DRD2 (0.84) | DRD2DRD3DRD4HTR1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-RE43244-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-RE42802-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| EP-2098511-A1 | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring | Solvias AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-6998405-B2 | Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia | H. LUNDBECK A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | disclosed |
| US-6683087-B2 | TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION | AXON BIOCHEMICALS B.V. (NL) | 2004-01-27 | — | — | US | disclosed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | disclosed |
| EP-0641320-B1 | SUBSTITUTED (S)-3-PHENYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE AUTORECEPTOR ANTAGONISTS | UPJOHN CO (US) | 2001-05-30 | — | — | EP | disclosed |
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | DRD2 9/4885DRD3 18/4885DRD4 38/4885 |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | DRD2 4030/4885DRD3 3548/4885DRD4 3345/4885 |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | DRD2 9/4885DRD3 18/4885DRD4 40/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | DRD2 4394/4885DRD3 3965/4885DRD4 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.